Monofree (Dexamethasone Phosphate)

Dexamethasone phosphate, the active ingredient in Monofree, is a corticosteroid presented as a sterile ophthalmic solution for ocular use. It treats postoperative ocular inflammation, non‑infectious uveitis, allergic conjunctivitis and other inflammatory eye conditions in adult patients.

GNH USA supplies Monofree as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Monofree (dexamethasone phosphate) is a glucocorticoid used to manage inflammatory eye conditions.

- Post‑operative ocular inflammation: reduces swelling, pain and redness after eye surgery. - Non‑infectious uveitis: suppresses intra‑ocular inflammation and helps prevent tissue damage. - Allergic conjunctivitis: alleviates itching, redness and swelling caused by allergic reactions.

Adverse reactions may occur with ocular use of dexamethasone phosphate.

Common Side Effects: - Transient eye irritation or burning sensation. - Mild conjunctival hyperemia. - Temporary increase in intra‑ocular pressure. - Blurred vision that resolves after discontinuation. - Mild headache.

Serious or Rare Side Effects: - Persistent elevation of intra‑ocular pressure leading to glaucoma. - Secondary ocular infections such as bacterial or fungal keratitis. - Cataract formation with prolonged use. - Severe allergic reaction with eyelid edema and erythema. - Delayed wound healing after ocular surgery.

Use Monofree only under the direction of an eye care professional. - Pregnancy: safety not established; avoid unless benefits outweigh risks. - Breastfeeding: unknown; consider potential exposure to infant. - Pre‑existing glaucoma or ocular hypertension: monitor intra‑ocular pressure closely. - Long‑term therapy: limit duration to reduce risk of cataract or pressure rise. - Store at room temperature: keep in original container, protect from light and moisture.

Dexamethasone phosphate may interact with other ocular or systemic agents.

Major Interactions (Avoid): - Concurrent use of potent intra‑ocular steroids: risk of additive pressure increase. - Anticholinergic eye drops: may reduce steroid absorption.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory eye drops: possible additive irritation. - Systemic CYP3A4 inhibitors: may modestly increase systemic exposure. - Antifungal eye preparations: monitor for reduced antifungal efficacy.